Iris Grossman

1.8k citations

43 papers · 1.4k indexed · h-index 23

Impact in

Biological Psychiatry top 5%
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism

Papers in ⓘ

Pharmacology 8
- Pharmacogenetics and Drug Metabolism 8
Immunology 11
- Immunotherapy and Immune Responses 5

Co-authors: Deborah Fass (6 shared papers)Michael R. Hayden (14 shared papers)Assaf Alon (3 shared papers)David B. Goldstein (5 shared papers)Tal Ilani (3 shared papers)Rebecca Kusko (6 shared papers)Michal Geva (5 shared papers)Sidney Cohen (1 shared paper)
Journals: Alzheimer s & Dementia (3 papers)Scientific Reports (2 papers)Genetics in Medicine (2 papers)Neurology (2 papers)Pharmacogenomics (2 papers)
Partner nations: Israel United States United Kingdom

In The Last Decade

Iris Grossman

43 papers receiving 1.3k citations

Peers

Countries citing papers authored by Iris Grossman

Since Specialization

Citations

This map shows the geographic impact of Iris Grossman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iris Grossman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iris Grossman more than expected).

Fields of papers citing papers by Iris Grossman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iris Grossman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iris Grossman. The network helps show where Iris Grossman may publish in the future.

Co-authors

The 25 scholars most cited alongside Iris Grossman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Iris Grossman Line = papers co-authored together Iris Grossman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Secreted Disulfide Catalyst Controls Extracellular Matrix Composition and Function Science ·Tal Ilani, Assaf Alon, Iris Grossman, Ben Horowitz, Elena Kartvelishvily, Sidney Cohen, Deborah Fass	2013	139
2	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor Proceedings of the National Academy of Sciences ·Joel Kaye, Victor Piryatinsky, Tal Birnberg, Tal Hingaly, Emanuel Raymond, Rina Kashi, Einat Amit‐Romach, Ignacio Caballero, Fadi Towfic, Mark A. Ator, Efrat Rubinstein, Daphna Laifenfeld, Aric Orbach, Doron Shinar, Yael Marantz, Iris Grossman, Volker Knappertz, Michael R. Hayden, Ralph Laufer	2016	118
3	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease Neurobiology of Disease ·Daniel A. Ryskamp, Jun Wu, Michal Geva, Rebecca Kusko, Iris Grossman, Michael R. Hayden, Ilya Bezprozvanny	2016	105
4	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis European Journal of Human Genetics ·Anna C. Need, Richard S.E. Keefe, Dongliang Ge, Iris Grossman, Sam Dickson, Joseph P. McEvoy, David B. Goldstein	2009	77
5	The dynamic disulphide relay of quiescin sulphydryl oxidase Nature ·Assaf Alon, Iris Grossman, Yair Gat, Vamsi K. Kodali, Frank DiMaio, Tevie Mehlman, Gilad Haran, David Baker, Colin Thorpe, Deborah Fass	2012	68
6	Pridopidine activates neuroprotective pathways impaired in Huntington Disease Human Molecular Genetics ·Michal Geva, Rebecca Kusko, Holly Soares, Kevin Fowler, Tal Birnberg, Steve Barash, A. Merenlender Wagner, Tania Fine, Andrew C. Lysaght, Brian Weiner, Yoonjeong Cha, Sarah Kolitz, Fadi Towfic, Aric Orbach, Ralph Laufer, Ben Zeskind, Iris Grossman, Michael R. Hayden	2016	65
7	Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers Pharmacogenetics and Genomics ·Iris Grossman, Nili Avidan, Clara Singer, Dan Goldstaub, Liat Hayardeny, Eli Eyal, Edna Ben‐Asher, Tamar Paperna, Itsik Pe’er, Doron Lancet, J. Beckmann, Ariel Miller	2007	54
8	TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial Alzheimer s & Dementia ·Allen D. Roses, Michael W. Lutz, Donna G. Crenshaw, Iris Grossman, Ann M. Saunders, William Gottschalk	2013	53
9	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). PubMed ·David B. Matchar, Mugdha Thakur, Iris Grossman, Douglas C McCrory, Lori A. Orlando, David C. Steffens, David B. Goldstein, Kathryn E Cline, Rebecca N Gray	2007	50
10	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson’s disease: a pharmacogenetic study Brain ·Mario Masellis, S.Karen Collinson, Natalie Freeman, Maria Tampakeras, J Lévy, A. Tchelet, Eli Eyal, Elijahu Berkovich, Rom E. Eliaz, Victor Abler, Iris Grossman, Cheryl Fitzer‐Attas, Arun K. Tiwari, Michael R. Hayden, James L. Kennedy, Anthony E. Lang, Jo Knight, (unknown)	2016	49
11	Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations PLoS ONE ·Colton L. Linnertz, Ann M. Saunders, Michael W. Lutz, Donna M. Crenshaw, Iris Grossman, Daniel K. Burns, Keith E. Whitfield, Michael A. Hauser, Jeanette McCarthy, Megan Ulmer, Rand Allingham, Kathleen A. Welsh‐Bohmer, Allen D. Roses, Ornit Chiba‐Falek	2012	46
12	Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors Genetics in Medicine ·Mugdha Thakur, Iris Grossman, Douglas C McCrory, Lori A. Orlando, David C. Steffens, Kathryn E Cline, Rebecca N Gray, Jennifer Farmer, Georgette Dejesus, Cara O’Brien, Gregory P. Samsa, David B. Goldstein, David B. Matchar	2007	43
13	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study Genetics in Medicine ·Iris Grossman, Patrick F. Sullivan, Sophie Nicole, Youfang Liu, Jeffrey R. Dawson, Curtis Gumbs, Andrea Gaedigk, J. Steven Leeder, Joseph P. McEvoy, Michael E. Weale, David B. Goldstein	2008	36
14	Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse Molecular Neurodegeneration ·Rebecca Kusko, Jennifer Dreymann, Jermaine Ross, Yoonjeong Cha, Renan Escalante-Chong, Marta Garcia‐Miralles, Liang Tan, Michael E. Burczynski, Ben Zeskind, Daphna Laifenfeld, Mahmoud A. Pouladi, Michal Geva, Iris Grossman, Michael R. Hayden	2018	35
15	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice JCI Insight ·Marta Garcia‐Miralles, Michal Geva, Jing Tan, Nur Amirah Binte Mohammad Yusof, Yoonjeong Cha, Rebecca Kusko, Liang Tan, Xiaohong Xu, Iris Grossman, Aric Orbach, Michael R. Hayden, Mahmoud A. Pouladi	2017	34
16	Global Pharmacogenetics: Genetic Substructure of Eurasian Populations and its Effect on Variants of Drug-Metabolizing Enzymes Pharmacogenomics ·О. А. Макеева, В. А. Степанов, В. П. Пузырев, David B. Goldstein, Iris Grossman	2008	33
17	Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings Cells ·Brian Schwartz, Vaishnavi Rajagopal, Cynthia Smith, Evan Cohick, Gavin Whissell, Maribet Gamboa, Rutuja Pai, Alla A. Sigova, Iris Grossman, David Bumcrot, Kavitha Sasidharan, Stefano Romeo, Alfica Sehgal, Piero Pingitore	2020	32
18	Bio-markers of disease activity and response to therapy in multiple sclerosis Clinical Neurology and Neurosurgery ·Ariel Miller, Lea Glass‐Marmor, Michal Abraham, Iris Grossman, Sarah Shapiro, Yanina Galboiz	2004	31
19	Routine Pharmacogenetic Testing in Clinical Practice: Dream or Reality? Pharmacogenomics ·Iris Grossman	2007	30
20	Alzheimer’s disease: diagnostics, prognostics and the road to prevention The EPMA Journal ·Iris Grossman, Michael W. Lutz, Donna G. Crenshaw, Ann M. Saunders, Daniel K. Burns, Allen D. Roses	2010	29

About Iris Grossman

Iris Grossman is a scholar working on Pharmacology, Immunology, Family Practice, Biological Psychiatry and Cell Biology, having authored 43 papers that have together received 1.4k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (8 papers), Endoplasmic Reticulum Stress and Disease (6 papers), Immunotherapy and Immune Responses (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Alzheimer's disease research and treatments (4 papers), Neurological disorders and treatments (4 papers), Multiple Sclerosis Research Studies (4 papers) and Pharmaceutical studies and practices (3 papers). The work is most often cited by research in Biological Psychiatry (68 citations), Pharmacology (147 citations), Cellular and Molecular Neuroscience (251 citations), Neurology (164 citations) and Psychiatry and Mental health (144 citations). Iris Grossman has collaborated with scholars based in Israel, United States and United Kingdom. Frequent co-authors include Deborah Fass, Michael R. Hayden, Assaf Alon, David B. Goldstein, Tal Ilani, Rebecca Kusko, Michal Geva, Sidney Cohen, Elena Kartvelishvily and Allen D. Roses. Their work appears in journals such as Alzheimer s & Dementia, Scientific Reports, Genetics in Medicine, Neurology and Pharmacogenomics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact